Time |
Topic |
Speaker(s) |
1:00 p.m. - 1:30 p.m. |
Introduction to Radiopharmaceutical Therapy |
Annick van den Abbeele, MD |
1:30 p.m. - 2:15 p.m. |
Physics of RPTs
- Imaging
- Isotopes
- Dosimetry methods
- Radiation safety
|
Robert Hobbs, PhD
Stephen Graves, PhD |
2:15 p.m. - 2:45 p.m. |
Pharmacology and radiobiology of RPTs
- Pharmacokinetics and Biodistribution
- RBE
- Radiation toxicities
|
Susan Knox, MD, PhD
Ana Kiess, MD, PhD |
2:45 p.m. - 3:30 p.m. |
Clinical Studies of RPTs
- Published controlled trials of Ra-223, Lu-177 DOTATATE, and I-131 MIBG
- Ongoing trials of Lu-177 PSMA agents
- Published reports of Y-90 microspheres
|
Michael Morris, MD
Neeta Pandit-Taskar, MD |
3:30 p.m. - 4:00 p.m. |
Infrastructure, Workflow, and Finances of RPTs |
John Buatti, MD
|
4:00 p.m. - 4:15 p.m. |
Break |
|
4:15 p.m. - 5:00 p.m. |
Breakout Sessions I:
These sessions will focus on practical aspects of specific RPTs including patient selection and indications, logistics of imaging and therapy, followup and potential toxicities. These 2 successive sessions will have the same 5 options, and attendees will choose one per session. There will be time reserved for Q&A.
- Radium-223
- Lu-177 DOTATATE
- Lu-177 PSMA agents
- I-131 MIBG
- Y-90 Microspheres
|
Richard Stock, MD (Ra-223)
Lilja Solnes, MD (Lu-177 DOTATATE)
Ana Kiess, MD, PhD (Lu-177 PSMA)
Neeta Pandit-Taskar, MD (I-131 MIBG)
Andrew Kennedy, MD (Y-90 Microspheres)
|
5:00 p.m. - 5:15 p.m. |
Break |
|
5:15 p.m. - 6:00 p.m. |
Breakout Sessions II:
These sessions will focus on practical aspects of specific RPTs including patient selection and indications, logistics of imaging and therapy, followup and potential toxicities. These 2 successive sessions will have the same 5 options, and attendees will choose one per session. There will be time reserved for Q&A.
- Radium-223
- Lu-177 DOTATATE
- Lu-177 PSMA agents
- I-131 MIBG
- Y-90 Microspheres
|
Richard Stock, MD (Ra-223)
Lilja Solnes, MD (Lu-177 DOTATATE)
Ana Kiess, MD, PhD (Lu-177 PSMA)
Neeta Pandit-Taskar, MD (I-131 MIBG)
Andrew Kennedy, MD (Y-90 Microspheres) |